Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models
Shijie Li, Nan Li, Xiangming Liu, Yueqi Cai, Mukai Wang, Huimin Wang, Yang-Xin Fu, Zaopeng Yang
Shijie Li, Nan Li, Xiangming Liu, Yueqi Cai, Mukai Wang, Huimin Wang, Yang-Xin Fu, Zaopeng Yang
View: Text | PDF
Research Article Immunology Oncology

Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models

  • Text
  • PDF
Abstract

T cell engagers (TCEs) have achieved transformative success in B cell malignancies but show limited efficacy in solid tumors with severe toxicity. We propose that TCR signaling without IL-2 might limit the function of tumor-infiltrating lymphocytes (TILs). Here, we showed that insufficient IL-2 signaling is a key bottleneck for sustaining TCE-induced T cell function. Although exogenous IL-2 enhances TCE efficacy, its systemic administration causes more severe toxicity. We engineered a protease-activatable dual-variable domain (DVD) as a pro-antibody to reduce αCD3 off-tumor toxicity. Furthermore, we designed 3 additional mutations for IL-2 (3E) with markedly reduced receptor affinity, which remained inactive in the periphery. By coengineering the DVD and 3E into a single pro-drug molecule (DVD-3E), we achieved conditional IL-2 and TCR cosignaling strictly dependent on cis CD3 engagement within the tumor microenvironment (TME) upon protease cleavage. This logic-gated design restricted both TCE and cytokine activity to the TME, enabling potent antitumor responses without systemic toxicity. Mechanistically, DVD-3E enhanced not only the persistence and effector function of preexisting intratumoral T cells but also expanded TCF1+ TILs, mitigating exhaustion and enabling durable systemic immunity. These findings define a new design principle for logic-gated TCEs that achieve a favorable balance between efficacy and safety, offering a strategy to overcome current therapeutic resistance.

Authors

Shijie Li, Nan Li, Xiangming Liu, Yueqi Cai, Mukai Wang, Huimin Wang, Yang-Xin Fu, Zaopeng Yang

×

Figure 1

Exogenous IL-2 enhances TCE-mediated T cell cytotoxicity while maintaining effector T cell functionality.

Options: View larger image (or click on image) Download as PowerPoint
Exogenous IL-2 enhances TCE-mediated T cell cytotoxicity while maintaini...
(A) Growth of MC38-CLDN tumors in hCD3-KI mice. Mice were randomly grouped and i.p. treated with PBS or 200 pmol TCE once every 3 days for 5 doses. n = 5 mice per group. (B) Multiround killing of SNU1-CLDN cells by TCE in human PBMC coculture, with an effector target ratio of 1:3; tumor cell viability was assessed every 48 h. (C) Volcano plot of differentially expressed genes between effector T (Teff) and exhausted T (Tex) cells. Genes with adjusted P < 0.01 are shown; upregulated genes are highlighted in red and downregulated genes in blue. (D) KEGG pathway enrichment bubble plot based on Tex_Teff downregulated genes. Only pathways with an adjusted P value < 0.05 are shown. (E) PBMCs from different donors were repeatedly stimulated with human T cell-activating CD3/CD28 Dynabeads. Culture supernatants were collected every 48 h for IL-2 measurement, followed by the addition of fresh beads. (F and G) Tumor cell killing by human PBMCs (F) and IFN-γ levels in culture supernatants or in the presence of TCE, IL-2, or both (G), cocultured with an effector-to-target (E/T) cell ratio of 1:3 for 72 h. (H) Tumor cell killing by human PBMCs in serial dilutions of TCE or TCE-IL2 with an E/T ratio of 1:1 for 48 h. (I–K) Tumor growth (I) and body weight change (J) in the MC38-CLDN model following 200 pmol TCE or TCE-IL2 treatment. Serum cytokine (K) levels 24 h after first treatment. n = 5 mice per group. Data are shown as mean ± SEM and are representative of at least 2 independent experiments. Individual data points shown in the figures represent independent biological replicates. Statistical analysis was performed using 1-way (B, F, G, and K) or 2-way (A and I) ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts